PRESS-RELEASE ·Filed Mar 18, 2026
Press release: earnings
Actionable Insight • Neutral
Traders should prepare for a potentially muted reaction post-release due to lack of a conference call; monitor the earnings press release closely for any surprises in financials or pipeline updates.
Final — all horizons settled through T+60d
SPRO ▲ +17.81% at T+60d
NEUTRAL call ✓ call won +17.81% · α vs SPY +3.47% · entry $2.47 → $2.91
T+1d
-4.05%
call -4.05% · α -2.31%
$2.37
settled 7mo ago
T+5d
-4.05%
call -4.05% · α -1.84%
$2.37
settled 6mo ago
T+20d
+11.34%
call +11.34% · α +3.71%
$2.75
settled 6mo ago
T+60d
+17.81%
call +17.81% · α +3.47%
$2.91
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Spero Therapeutics announced it will release its Q4 and full-year 2025 financial results on March 26, 2026, after market close. The company will not host a conference call, limiting immediate investor engagement and real-time clarification of results.
Key Facts
- Spero Therapeutics will report Q4 and full-year 2025 financial results on March 26, 2026, after market close.
- No conference call is planned, which may limit investor interaction and near-term market reaction.
- Company remains focused on clinical-stage development for rare and high unmet need diseases.
Financial Impact
Results pending — no financial figures provided in this release
revenueepscashFlow
Risk Factors
- Lack of management commentary via conference call increases risk of misinterpretation or delayed reaction to results.
- As a clinical-stage biopharma with no commercial revenue, financial results will likely reflect continued R&D spend and cash burn.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258588 |
13 reports for SPRO
63% Hit rate best @ T+20▲ +14.59%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | EFFECT | $1.13 $1.13 | · 0.00% | ▼ −0.34% | $1.19 (−5.31%) |
Aug 28, 2026 4w ago | 8-K | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.19 (+2.46%) |
Aug 28, 2026 4w ago | S-3 | $1.22 $1.19 | ▲ +2.46% | ▲ +2.32% | $1.19 (+2.46%) |
Aug 12, 2026 7w ago | Press Release | $1.24 $1.22 | ▼ −1.61% | ▲ +0.35% | $1.19 (−4.03%) |
Jul 14, 2026 11w ago | 8-K | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.19 (−30.00%) |
Jul 14, 2026 11w ago | Press Release | $1.70 $1.44 | ▼ −15.29% | ▼ −14.00% | $1.19 (−30.00%) |
Jun 25, 2026 14w ago | 8-K | $2.26 $2.20 | ▼ −2.65% | ▼ −4.82% | $1.19 (−47.35%) |
Jun 22, 2026 14w ago | 8-K | $2.15 $2.26 | ▲ +5.12% | ▲ +4.10% | $1.19 (−44.65%) |
Jun 17, 2026 15w ago | Press Release | $2.11 $2.10 | ▼ −0.47% | ▲ +0.57% | $1.19 (−43.60%) |
May 13, 2026 20w ago | 8-K | $2.76 $2.69 | ▼ −2.54% | ▼ −1.82% | $1.19 (−56.88%) |
Showing 10 of 13
US Market Status
Market Closed — Opens Mon (65h)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access